5LH0 Stock Chart & Stats
€0.10
<€0.01(5.41%)
At close: 4:00 PM EDT
€0.10
<€0.01(5.41%)
Day’s Range― - ―
52-Week Range€0.01 - €2.27
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.22M
Enterprise Value-€1.84M
Total Cash (Recent Filing)€40.99M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-56.14
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.07
Shares Outstanding44,588,066
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of debt reduces interest obligations and refinancing exposure while preserving financial flexibility for clinical development. Although the company still needs external capital, a debt-free structure avoids adding lender claims and gives management more optionality in funding future milestones.
Focused Clinical AssetRMC-035 gives Guard Therapeutics a clearly defined therapeutic focus around kidney disease, oxidative stress, and inflammation. A disease-modifying approach could support meaningful clinical differentiation if development succeeds, creating a potential foundation for future commercial value.
Reduced Operating LossThe smaller trailing loss indicates some improvement in expense control or operating burn compared with the prior annual period. While the company remains unprofitable, continued progress in controlling costs could extend its development runway and reduce the pace of required financing.
Bears Say
No Commercial RevenueZero revenue means the business currently lacks an operating income stream to support research, development, and corporate costs. Its earnings outlook therefore depends heavily on future clinical milestones and eventual product success, leaving little evidence of near-term self-sustaining commercial economics.
Persistent Cash BurnSustained negative operating and free cash flow means Guard Therapeutics cannot currently fund its activities from internally generated cash. Continued development will therefore require external capital, making financing availability and the terms of future funding important risks to business continuity.
Shrinking Equity BaseThe substantial reduction in equity shows that shareholder capital is being consumed rather than compounded as losses continue. This weakens the financial cushion available for development and raises the prospect of further dilution or other costly financing to sustain operations.
5LH0 FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was €0.01 and its highest was €2.27 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is €4.22M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is Nov 12, 2026 which is in 19 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on Aug 20, 2026. The company reported -€0.02 earnings per share for the quarter.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 44,588,066 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -€0.02 in its last earnings report. Following the earnings report the stock price went up 5.714%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in DE:5LH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
Technical Analysis
OncoZenge AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
Modus Therapeutics Holding AB
―
Spago Nanomedical AB
―